GSK to team up with Sino Biopharma for China launch of hepatitis B treatment

GSK ​on Monday ‌said it ​had ​entered into ⁠a ​strategic collaboration ​with Hong Kong-listed ​Sino ​Biopharmaceutical to ‌accelerate ⁠the launch of ​its ​hepatitis ⁠B treatment ​bepirovirsen ​in ⁠mainland ⁠China.

Reuters • May 11, 2026

Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.

Business Wire • May 7, 2026

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.

MarketBeat • May 2, 2026

Big Pharma M&A set for mega year as patent expiries drive deal urgency

Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.

Reuters • May 1, 2026

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight rating on GSK PLC (LSE:GSK, NYSE:GSK) with a June 2027 price target of £17, arguing that near-term earnings upgrade potential is limited and that the pharmaceutical group's longer-term outlook remains contingent on pipeline success and the execution of new product launches. Analyst Zain Ebrahim made modest forecast changes following GSK's first-quarter 2026 results, including foreign exchange-related adjustments of 0% to 1% to sales forecasts across 2026 to 2031 and upgrades of 1% to 2% to core operating profit estimates.

Proactive Investors • Apr 30, 2026

Why GSK (GSK) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Apr 30, 2026

GSK beats quarterly profit estimates on strength in respiratory, general medicines

British drugmaker ​GSK reported first-quarter ‌profit above analysts' expectations ​on Wednesday, ​helped by strong sales ⁠of ​its respiratory and ​other general medicines.

Reuters • Apr 29, 2026

GSK reaffirms 2026 guidance after strong first-quarter performance

GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per share both expected to rise between 7% and 9% at constant exchange rates. Turnover growth is forecast to be between 3% and 5%, supported by expectations of low double-digit growth in Specialty Medicines, offset by low single-digit declines to stable performance in both Vaccines and General Medicines.

Proactive Investors • Apr 29, 2026

GSK Earnings Boosted by Higher Specialty Medicine Sales

The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier.

WSJ • Apr 29, 2026

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.

Zacks Investment Research • Apr 29, 2026